Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily

Yifan Zhai, Jingyi Yu, Luisa Iruela-Arispe, Wei Qun Huang, Zheng Wang, Andrew J. Hayes, Jiamo Lu, Gongwei Jiang, Lorena Rojas, Marc E. Lippman, Jian Ni, Guo Liang Yu, Lu Yuan Li*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

90 Scopus citations


Recently, we reported a novel protein of the tumor necrosis factor (TNF) superfamily, named vascular endothelial cell growth inhibitor (VEGI), which is expressed predominantly in endothelial cells. When a secreted form of this new protein was overexpressed in mouse colon cancer cells, the growth of tumors formed by these cells in black mice was inhibited. We now report that recombinant VEGI inhibits the proliferation of endothelial cells but not that of other types of cells examined. The protein also inhibits formation of capillary-like structures by endothelial cells in collagen gels, and the growth of capillaries into collagen gels placed on the chick chorioallantoic membrane. The anticancer potential of VEGI was examined in a breast cancer xenograft tumor model in which the cancer cells were co-injected with Chinese hamster ovary cells overexpressing a secreted form of the protein. The co- injection resulted in potent inhibition of xenograft tumor growth. Our findings are consistent with the view that VEGI is an endothelial cell- specific negative regulator of angiogenesis.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalInternational Journal of Cancer
Issue number1
StatePublished - Jul 2 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily'. Together they form a unique fingerprint.

Cite this